B
BioXcel Therapeutics, Inc. (BTAI)
NCM – Real Time Price. Currency in USD
1.31
+0.06 (4.80%)
At close: Jun 26, 2026, 4:00 PM EDT
1.30
-0.01 (-0.76%)
After-hours: Jun 26, 2026, 7:53 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
1.31
+0.06 (4.80%)
At close: Jun 26, 2026, 4:00 PM EDT
1.30
-0.01 (-0.76%)
After-hours: Jun 26, 2026, 7:53 PM EDT
No Data
There are no news for this stock.
Total debt $100.3M significantly exceeds cash reserves ($17.2M), raising financial stability concerns
Total current liabilities $55.0M surpass Total current assets $33.9M, signaling liquidity issues
Debt-to-equity ratio (-1.0) is well below the industry average (-0.8), showcasing prudent financial management
Interest coverage ratio (-2.4x) is dangerously low, suggesting debt repayment risks
Negative free cash flow -$11.8M limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 0.62 | 2.52 | 4.0 | |
| Quick ratio | 0.61 | 1.78 | 4.0 | |
| Debt to Equity | N/A | -0.80 | 1.0 | |
| Debt to Assets | 2.95 | 0.73 | 1.0 | |
| Interest coverage | -2.41 | -13.90 | 1.0 | |
| Weighted average score | 2.2 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 375K | 1M | 2M | 642K | 680K |
| Gross Profit | 28K | -198K | -186K | 178K | -35K |
| Operating Income | -158M | -166M | -63M | -50M | -50M |
| Net Income | -166M | -179M | -60M | -70M | -75M |
| EBITDA | -158M | -166M | -63M | -49M | -50M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | 236.1 | 82.76 | 10 |
| Next quarter | 304.95 | 78.21 | 10 |
| Current year | 157.94 | 70.9 | 10 |
| Next year | 1043.34 | 8.05 | 8.0 |
| Weighted average score | 9.5 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | -19.52 | -1.15 | 6.9 | 16.9 | 4.0 |
| Y/Y | 22.62 | -74.94 | 64 | 1.94 | 6.0 |
| 3y average | 86.85 | 13.81 | 49.29 | 19.71 | 9.3 |
| 5y average | 451.71 | -8.73 | 18.97 | -5.74 | 5.3 |
| Weighted average score | 6.2 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |